DDInter1258 DDInter1658
Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Naldemedine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Naldemedine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mifepristone
Naldemedine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Istradefylline
Naldemedine {u} may lead to a major life threatening interaction when taken with {v} Phenobarbital
Naldemedine {u} may lead to a major life threatening interaction when taken with {v} Apalutamide
Naldemedine may cause a minor interaction that can limit clinical effects when taken with Modafinil
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Mifepristone
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Naldemedine may lead to a major life threatening interaction when taken with Phenobarbital
Naldemedine may lead to a major life threatening interaction when taken with Apalutamide